Lund, Sweden, October 16 2019
ImmuneBiotech AB, the probiotic and microbiome company, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted a US patent protecting its probiotic product GutMagnific® in the USA. The patent US10.632,169B2 covers the composition of matter and use of GutMagnific®, this is an essential asset for ImmuneBiotech to become an emerging key player in the US – the largest market for probiotic dietary supplement.
GutMagnific® is a super-consortium (combination) of five probiotic lactobacillus strains, scientifically designed to address the underlying key causes of IBS and is sold as a food supplement www.GutMagnific.com. GutMagnific® is the first product in a new probiotic category ImmuneBiotics™ where products are developed using pharmaceutical precision focused on achieving a healthy balance between the microbiome, the immune system, and the intestinal barrier.
“I’m extremely pleased to have our first probiotic product GutMagnific® protected by a US patent confirming our outstanding innovation and representing a quality label for ImmuneBiotech. We are of course moving towards the US, the largest probiotic supplement market, with annual sales of USD 2 500 million. GutMagnific® has already gained attention from American consumers, business partners and even medical doctors. We are currently evaluating best strategies to enter the US market including an awarded Catalyst project by Business Sweden having their Chicago office engaged to find best strategies and partners”. said Shahram Lavasani, CEO of ImmuneBiotech.